Atherosclerosis
Volume 195, Issue 2 , Pages 254-261 , December 2007

Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: Role for the urokinase receptor

  • Julia Kiyan

      Affiliations

    • Hannover Medical School, Carl-Neuberg Straße 1, Hannover D-30625, Germany
    • Both authors contributed equally to this work.
    • ,
  • Angelika Kusch

      Affiliations

    • Medical Faculty of the Charité – Max Delbrück Center, Berlin, Germany
    • Both authors contributed equally to this work.
    • ,
  • Sergey Tkachuk

      Affiliations

    • Hannover Medical School, Carl-Neuberg Straße 1, Hannover D-30625, Germany
    • ,
  • Jochen Krämer

      Affiliations

    • Medical Faculty of the Charité – Max Delbrück Center, Berlin, Germany
    • ,
  • Hermann Haller

      Affiliations

    • Hannover Medical School, Carl-Neuberg Straße 1, Hannover D-30625, Germany
    • ,
  • Rainer Dietz

      Affiliations

    • Medical Faculty of the Charité – Max Delbrück Center, Berlin, Germany
    • ,
  • Graham Smith

      Affiliations

    • AstraZeneca, Macclesfield, Cheshire, UK
    • ,
  • Inna Dumler

      Affiliations

    • Hannover Medical School, Carl-Neuberg Straße 1, Hannover D-30625, Germany
    • Medical Faculty of the Charité – Max Delbrück Center, Berlin, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 511 532 2395; fax: +49 511 2713.

Received 12 July 2006 ,Revised 11 December 2006 ,Accepted 21 December 2006.

References 

  1. Steins M, Padro BT, Schwaenen C, et al. Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagul Fibrinolysis. 2004;15:383
  2. Okada SS, Golden MA, Raghunath PN, et al. Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo. Thromb Haemost. 1998;80:140
  3. Salame MY, Samani NJ, Masood I, deBono DP. Expression of the plasminogen activator system in the human vascular wall. Atherosclerosis. 2000;152:19
  4. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932
  5. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 2004;25:450
  6. Lusis AJ. Atherosclerosis. Nature. 2000;407:233
  7. Kenagy RD, Vesti BR, Clowes AW. The urokinase receptor mediates basic fibroblast growth factor-dependent smooth muscle cell migration through baboon aortic explants. Atherosclerosis. 2002;162:63
  8. Okada SS, Tomaszewski JE, Barnathan ES. Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro. Exp Cell Res. 1995;217:180
  9. Kiyan Y, Kiyan R, Haller H, Dumler I. Urokinase-induced signaling in human vascular smooth muscle cells are mediated by PDGFR. The EMBO J. 2005;24:1787
  10. Kunigal S, Kusch A, Tkachuk N, et al. Monocyte-expressed urokinase inhibits vascular smooth muscle cell growth by activating Stat1. Blood. 2003;102:4377
  11. Quax PH, Lamfers ML, Lardenoye JH, et al. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation. 2001;103:562
  12. Lamfers MLM, Grimbergen JM, Aalders MC, et al. Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1, ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. Circ Res. 2002;91:945
  13. Davington J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109:III
  14. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89
  15. Seasholtz TM, B. JH. Rho signaling in vascular diseases. Mol Interv. 2004;4:348
  16. Kiian I, Tkachuk N, Haller H, Dumler I. Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/PI3-K signalling pathway. Thromb Haemost. 2003;89:904
  17. Kjoller L, Hall AJ. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol. 2001;152:1145
  18. Christen T, Verin V, Bochaton-Piallat ML, et al. Mechanisms of neointima formation and remodeling in the porcine coronary artery. Circulation. 2001;103:882
  19. Noda-Heiny H, Daugherty A, Sobel BE. Augmented urokinase receptor expression in atheroma. Arterioscler Thromb Vasc Biol. 1995;15:37
  20. Bi X, Baudry M, Liu J, et al. Inhibition of geranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. J Biol Chem. 2004;279:48238
  21. Endres M, Laufs MD. Effects of statins on endothelium and signaling mechanisms. Stroke. 2004;35:2708
  22. Morikawa S, Takabe W, Mataki C, et al. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb. 2004;11:62
  23. Kleemann R, Princen HMG, Emeis JJ, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-leiden transgenic mice. Circulation. 2003;108:1368
  24. Schafer K, Kaiser K, Konstantinides S. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haem. 2005;93:145
  25. Roldan AL, Cubellis MV, Masucci MT, et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 1990;9:467
  26. Hao H, Ropraz P, Verin V, et al. Heterogeneity of smooth muscle cell populations cultured from pig coronary artery. Arterioscler Thromb Vasc Biol. 2002;22:1093
  27. Vasudevan SS, Lopes N, Seshiah PN, et al. Mac-1 and Fas activities are concurrently required for execution of smooth muscle cell death by M-CSF-stimulated macrophages. Cardiovasc Res. 2003;59:723
  28. Sakamoto K, Murata T, Chuma H, Hori M, Ozaki H. Fluvastatin prevents vascular hyperplasia by inhibiting phenotype modulation and proliferation through extracellular signal-regulated kinase 1 and 2 and p38 mitogen-activated protein kinase inactivation in organ-cultured artery. Arterioscler Thromb Vasc Biol. 2005;25:327
  29. Chen CN, Li YSJ, Yeh YT, et al. Synergistic roles of platelet-derived growth factor-BB and interleukin-1β in phenotypic modulation of human aaortic smooth muscle cells. Proc Natl Acad Sci USA. 2006;103:2665
  30. Yamanaka Y, Hayashi K, Komurasaki T, et al. EGF family ligand-dependent phenotypic modulation of smooth muscle cells through EGF receptor. Biochem Biophys Res Commun. 2001;281:373
  31. Jiang M, Bujo H, Zhu Y, et al. Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells. Biochem Biophys Res Commun. 2006;348:1367

PII: S0021-9150(07)00026-3

doi: 10.1016/j.atherosclerosis.2006.12.030

Atherosclerosis
Volume 195, Issue 2 , Pages 254-261 , December 2007

Article Tools

* Image Usage & Resolution